marked.bio

anti-PD-1 antibody · antibody

camrelizumab

7 active trials across 7 of our biomarkers, targeting PD-1. Not approved for any biomarker on marked.bio yet.

Also known as SHR-1210.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRCA1/2 mutation 3 3 Phase 2
MSI-H / dMMR 2 5 Phase 2
ALK fusion 1 2 Phase 2
EGFR exon 19 deletion / L858R 1 2 Phase 2
KRAS G12C 1 2 Phase 2/3
KRAS G12D 1 2 Phase 2/3
BRAF V600E 0 2 –

Sponsors

Industry sponsors leading active biomarker-selected trials of camrelizumab.

  1. CrystalGenomics 1
  2. Jiangsu Hengrui 1

Trials

7 of 15 trials shown

  1. A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

    Not yet recruiting Phase 2/3 Jiangsu Hengrui Started 2024Primary completion 2028-10 NCT06335355

    adebrelimabpemetrexedcarboplatincamrelizumab

    Participants must have tumors with STK11 or KEAP1 or KRAS mutations.

    KRAS G12CKRAS G12DStatus may be outdated, last updated 2024-03-28Non-squamous Non-small Cell Lung Cancer

  2. Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

    Recruiting Phase 2 Fudan University Started 2024Primary completion 2026-06 NCT06516289

    HRS-1167Famitinibcamrelizumab

    Patients with pathogenic germline BRCA 1/2 mutation.

    BRCA1/2 mutationBRCA-Mutated Breast Carcinoma, HER2-negative Breast Cancer

  3. Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer

    Active, not recruiting Phase 2 Peking Union Medical College Hospital Started 2024Primary completion 2025-05 NCT06215677

    camrelizumab

    Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer

    MSI-H / dMMRColon Cancer, Mismatch Repair Deficiency, Immunotherapy

  4. Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    Recruiting Phase 2 CrystalGenomics Started 2023Primary completion 2026-08 NCT05841472

    camrelizumabpemetrexedcarboplatin

    Subject cannot be randomized before receiving the source document for EGFR mutation and ALK translocation.

    EGFR exon 19 deletion / L858RALK fusionStatus may be outdated, last updated 2023-08-30Non Squamous Non Small Cell Lung Cancer

  5. Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

    Recruiting Phase 2 Ying Lin Started 2022Primary completion 2024-06 NCT05761470

    camrelizumabfluzoparibnab-paclitaxel

    HRR gene mutation: at least one pathogenic or likely pathogenic variant in germline or somatic BRCA1, BCRA2 and PALB2 genes, or in germline ATM, BARD1, BRIP1, CDK12, CHEK2, RAD51C, RAD51D g…

    BRCA1/2 mutationStatus may be outdated, last updated 2023-03-09Her-2 Negative Breast Cancer, HRR Gene Mutation

  6. Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study

    Recruiting Phase 2 Peking University People's Hospital Started 2022Primary completion 2027-04 NCT05576389

    camrelizumabfluzoparib

    Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study

    BRCA1/2 mutationGermline BRCA-mutated HER2-negative Breast Cancer

  7. Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer

    Not yet recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Started 2022Primary completion 2025-11 NCT05550558

    anlotinibcamrelizumab

    Tumors must demonstrate MMRd and MLH1 methylation.

    MSI-H / dMMRStatus may be outdated, last updated 2022-09-28Endometrial Cancer